SLAMF6 Antibodies with Optimized CDR Sequences for Enhanced Immune Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cancers such as small cell lung cancer, non-small cell lung cancer, melanoma, breast cancer, and others that express SLAMF6 protein are limited in efficacy and specificity, as existing antibodies may not effectively target SLAMF6, leading to inadequate immune response and treatment outcomes.
Innovation Solution
Development of specific antibodies, including bispecific antibodies, that bind to SLAMF6 with high affinity, utilizing specific CDR sequences and frameworks to enhance immune cell activation and cytotoxicity, thereby improving treatment options for various cancers by targeting SLAMF6-expressing cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing antibodies are used to target SLAMF6, then treatment coverage is provided, but binding affinity and immune activation are insufficient
Solution Approach 1:
The patent applies parameter changes by modifying the antibody's CDR sequences and framework regions to optimize binding affinity to SLAMF6. Specifically, the invention uses CDR sequences with high identity to reference sequences (SEQ ID NOs: 5-10) and framework regions with ≥80% identity to human germline sequences, thereby improving treatment efficacy through precise parameter optimization rather than structural complexity
Solution Approach 2:
The patent applies local quality by making specific modifications to particular regions of the antibody molecule. The CDR regions are engineered with high sequence identity to ensure strong SLAMF6 binding, while framework regions are humanized to reduce immunogenicity. This localized optimization of different antibody regions resolves the contradiction between efficacy and complexity
2Reliability
If antibodies with high SLAMF6 binding affinity are developed, then immune cell activation is enhanced, but manufacturing complexity increases
Solution Approach 1:
The patent uses parameter changes by defining specific sequence identity thresholds (≥80% identity to human germline for framework regions, high identity for CDRs) that balance binding affinity with manufacturability. These standardized parameters enable consistent production while maintaining high immune activation capability through optimized CDR sequences
Solution Approach 2:
The patent employs humanized antibody sequences that closely resemble human germline sequences, making them more compatible with mammalian expression systems and easier to manufacture using standard biotechnological platforms. This approach prioritizes manufacturability while maintaining therapeutic effectiveness
3Measurement precision
If specific CDR sequences are used to enhance SLAMF6 binding, then binding affinity increases, but antibody diversity is reduced
Solution Approach 1:
The patent applies parameter changes by establishing specific sequence identity criteria for CDR regions (high identity to SEQ ID NOs: 5-10) that ensure consistent high-affinity binding to SLAMF6. This standardized approach maintains binding precision while the modular framework region design allows for controlled diversity in antibody variants
Data Source
AI summary
The present invention relates to antibodies and other therapeutic proteins directed against SLAM family member 6 (SLAMF6) also known as NTB-A or CD352, nucleic acids encoding such antibodies and therapeutic proteins, methods for preparing antibodies and other therapeutic proteins, and methods for the treatment of diseases, such as cancers, by using antibodies and other therapeutic proteins directed against SLAMF6.